Abstract:Background: Early screening using Low-Dose Computed Tomography (LDCT) can reduce mortality by non-small-cell-lung cancer (NSCLC), which contributed the most cancer-related death worldwide. Yet ~25% of the "suspicious" nodules identified by LDCT are confirmed to be benign through resection surgery, which adds to patients' discomfort and the burden of the healthcare system. In this prospective study, we set to develop a non-invasive liquid biopsy assay for distinguishing pulmonary malignancy from benign lung nodules using cfDNA fragmentomic profiling. Methods: An independent training cohort, which consisted of 193 patients with malignant nodule and 44 patients with benign nodule, was used to construct a machine learning model. Base models employing 4 different fragmentomics profiles were optimized using an automated machine learning (autoML) approach before being ensemble stacked to create the final predictive model. An independent validation cohort included 96 malignant nodules and 22 benign nodules, as well as an external test cohort containing 58 malignant nodules and 41 benign nodules, were used to assess the performance of the ensemble stacked model. Results: Our machine learning models showed excellent performances in detecting patients with malignant nodules. The AUCs reached 0.857 (0.782 - 0.932) and 0.860 (95% CI: 0.788 - 0.933) in the independent validation cohort and the external test cohort, respectively. The validation cohort achieved an excellent 68.2% specificity (95% CI: 45.1-86.1%) at the targeted 90% sensitivity (89.6%, 95% CI: 81.7-94.9%). An equivalently good performance was observed while applying the cutoff to the external cohort, which reached a specificity of 63.4% (95% CI: 46.9-77.9%) at 89.7% sensitivity (95% CI: 78.8-96.1%). Subgroup analysis for the independent validation cohort showed that the sensitivities for detecting various subgroups of nodule size ( 3cm: 100%; Unknown: 100%) and smoking history (Yes: 88.2%; No: 89.9%) all remained high among the lung cancer group. Additionally, the specificities for successfully identifying the benign nodules among different subgroups decrease as the size increase ( 3cm: 33.3%). Conclusions: Our cfDNA fragmentomics assay can provide a non-invasive approach to distinguish malignant nodules from the radiographically suspicious but pathologically benign nodules. Citation Format: Shun Xu, Ji Luo, Wanxiangfu Tang, Hua Bao, Jiajun Wang, Shuang Chang, Haimeng Tang, Zifang Zou, Xiaoxi Fan, Yang Liu, Changrui Jiang, Xue Wu, Yang Shao. Detecting pulmonary malignancy against benign nodules using non-invasive cfDNA fragmentomics assay. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited s); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl) nr 5394.

RNF213 gene mutation of circulating tumor DNA in early diagnosis of NSCLC using targeted next-generation sequencing

RNF213 gene mutation in circulating tumor DNA detected by targeted next‐generation sequencing in the assisted discrimination of early‐stage lung cancer from pulmonary nodules

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

MA17.03 Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and Ctdna

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer

Circulating Tumor Dna Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients

Identification of NR3C2 as a functional diagnostic and prognostic biomarker and potential therapeutic target in non-small cell lung cancer

Cell-free DNA assay for malignancy classification of high-risk lung nodules.

Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next‐Generation Sequencing With Insufficient Tumor Samples

Abstract 5394: Detecting pulmonary malignancy against benign nodules using non-invasive cfDNA fragmentomics assay

Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer

Clinical Utility of Circulating Genetically Anormal Cells in Stage I Small-Cell Lung Cancer Diagnosis.